Experimental Drug Shows Promise in Reversing Fatty Liver Disease by Targeting Gut Health
A potential new treatment for fatty liver disease has emerged from recent animal studies. Researchers tested an experimental drug called DT-109 and found it was able to reverse severe fatty liver disease by addressing damage in the gut.
The drug works by repairing the gut lining, which helps prevent harmful toxins from passing through the intestinal wall and reaching the liver. When these toxins are blocked from damaging liver tissue, the disease progression can be halted and potentially reversed.
Fatty liver disease, particularly MASH (metabolic dysfunction-associated steatohepatitis), has become increasingly common worldwide. Current treatment options remain limited, making this discovery particularly significant.
The research team noted that this gut-focused approach could also have implications for treating other conditions linked to gut health. Further studies will be needed to confirm the drug's safety and effectiveness in humans.